Yan Wei
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
-
- MicroRNA in disease regulation
Papers in
-
- Extracellular vesicles in disease 5
- RNA Interference and Gene Delivery 4
- Advanced biosensing and bioanalysis techniques 2
- Biomaterials 11
- Nanoparticle-Based Drug Delivery 11
- Co-authors
- Jiacan Su (9 shared papers)Shihao Sheng (5 shared papers)Can Xu (6 shared papers)Yong Gan (5 shared papers)Xiao Chen (2 shared papers)Fengjin Zhou (5 shared papers)Shiyan Guo (3 shared papers)Ke Xu (4 shared papers)
- Journals
- ACS Nano (3 papers)Acta Pharmaceutica Sinica B (2 papers)International Journal of Pharmaceutics (2 papers)Drug Discovery Today (2 papers)Journal of Nanobiotechnology (2 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Yan Wei
28 papers receiving 862 citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Biomaterials 269
- Cancer Research 110
- Pharmaceutical Science 43
- Biomedical Engineering 296
- Molecular Biology 381
Countries citing papers authored by Yan Wei
This map shows the geographic impact of Yan Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Wei more than expected).
Fields of papers citing papers by Yan Wei
This network shows the impact of papers produced by Yan Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Wei. The network helps show where Yan Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Yan Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases Hit paper breakdown → | 2023 | 129 |
| 2 | 2022 | 72 | |
| 3 | 2017 | 61 | |
| 4 | 2012 | 56 | |
| 5 | 2020 | 53 | |
| 6 | 2022 | 51 | |
| 7 | 2022 | 50 | |
| 8 | 2020 | 47 | |
| 9 | 2020 | 36 | |
| 10 | 2013 | 35 | |
| 11 | 2024 | 30 | |
| 12 | 2024 | 27 | |
| 13 | 2024 | 26 | |
| 14 | 2014 | 25 | |
| 15 | 2020 | 25 | |
| 16 | 2024 | 22 | |
| 17 | 2021 | 22 | |
| 18 | 2023 | 19 | |
| 19 | 2024 | 18 | |
| 20 | 2021 | 16 |
About Yan Wei
Yan Wei is a scholar working on Molecular Biology, Biomaterials, Oncology, Biomedical Engineering and Rheumatology, having authored 28 papers that have together received 866 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (11 papers), Nanoplatforms for cancer theranostics (5 papers), Extracellular vesicles in disease (5 papers), RNA Interference and Gene Delivery (4 papers), Osteoarthritis Treatment and Mechanisms (3 papers), Advanced biosensing and bioanalysis techniques (2 papers), Phagocytosis and Immune Regulation (2 papers) and Cell Adhesion Molecules Research (2 papers). The work is most often cited by research in Biomaterials (269 citations), Cancer Research (110 citations), Pharmaceutical Science (43 citations), Biomedical Engineering (296 citations) and Molecular Biology (381 citations). Yan Wei has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Jiacan Su, Shihao Sheng, Can Xu, Yong Gan, Xiao Chen, Fengjin Zhou, Shiyan Guo, Ke Xu, Yu-Xi Wang and Xinxin Zhang. Their work appears in journals such as ACS Nano, Acta Pharmaceutica Sinica B, International Journal of Pharmaceutics, Drug Discovery Today and Journal of Nanobiotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.